Daclatasvir 1009119-64-5 BMS-790052 Hepatitis C treatment Raw
Material Drug White
|Boiling Point:||1071.239 °C at 760 mmHg|
|Flash Point:||601.664 °C|
Daclatasvir (USAN, formerly BMS-790052, trade name Daklinza) is a
drug for the treatment of hepatitis C (HCV).
Daclatasvir has been tested in combination regimens with pegylated
interferon and ribavirin, as well as with other direct-acting
antiviral agents including asunaprevir and sofosbuvir.
It is on the World Health Organization's List of Essential
Medicines, a list of the most important medications needed in a
basic health system.
There has been significant controversy over the price that
Bristol-Myers Squibb has chosen to charge for the drug.
Daclatasvir (brand name Daklinza) is a new medication used to treat
Daclatasvir is an antiviral medicine that prevents hepatitis C
virus (HCV) from multiplying in your body.
|Uses 3||Daclatasvir is used to treat genotype 3 chronic hepatitis C in
adults without cirrhosis. This medicine is given together with
another drug called sofosbuvir.|
For others, daclatasvir can shorten treatment when added to
pegylated interferon and ribavirin. Successful treatment reduces
the risk of long-term complications of hepatitis C such as liver
cancer or needing a liver transplant.
- Daclatasvir is one of the new direct-acting antiviral drugs that
target different steps of the hepatitis C virus (HCV) lifecycle. It
is the first-ever approved HCV NS5A replication complex inhibitor,
meaning it interferes with a protein the virus uses to reproduce.
- Daclatasvir should be combined with other medications, which may
include other direct-acting antivirals that work differently –
sofosbuvir (Sovaldi) or the HCV protease inhibitor asunaprevir
(Sunvepra) – or pegylated interferon and ribavirin.
How effective is daclatasvir
Daclatasvir works better for some people than for others. Several
factors predict how well someone will respond, including HCV
genotype, extent of liver damage and previous treatment history.
People with liver cirrhosis do not respond as well as those with
mild or moderate liver fibrosis. Depending on which drugs
daclatasvir is combined with, people who are new to treatment may
have a better chance of being cured than those with little or no
response to prior treatment.
However, factors that traditionally predict poor response to
interferon-based therapy do not make as much difference with
interferon-free treatment. These factors may be overcome by
prolonging treatment or by adding another direct-acting antiviral